Cybin (HELP) Cash from Financing Activities (2020 - 2025)
Cybin (HELP) reported Cash from Financing Activities of $14.6 million for Q1 2025, down 89.68% on a YoY basis from $141.6 million in Q1 2024, and up 11511.23% quarter-over-quarter from -$128137.0 in Q4 2024.
Cybin (HELP) Cash from Financing Activities (2020 - 2025) Analysis & Trends
Cybin has reported Cash from Financing Activities for 6 years, with the latest figure at $14.6 million in Q1 2025.
- For the quarter ending Q1 2025, Cash from Financing Activities fell 89.68% year-over-year to $14.6 million; the trailing twelve-month figure through Mar 2025 stood at $14.1 million (down 92.55% YoY), and the FY2025 full-year result was $14.5 million, down 92.31% from the prior year.
- Cash from Financing Activities for Q1 2025 stood at $14.6 million, up from -$128137.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $141.6 million in Q1 2024, with the low at -$26.8 million in Q1 2023.
- Historically, Cash from Financing Activities has averaged $13.3 million across 5 years, with a median of $2.5 million in 2022.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities jumped 4613.52% — and 2023, when it sank 1162.71%.
- Cybin's Cash from Financing Activities stood at $1.1 million in 2021, then jumped by 129.43% to $2.5 million in 2022, then soared by 1045.56% to $29.2 million in 2023, then plunged by 100.44% to -$128137.0 in 2024, then soared by 11511.23% to $14.6 million in 2025.
- The last three Cash from Financing Activities figures came in at $14.6 million (Q1 2025), -$128137.0 (Q4 2024), and -$271229.8 (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Cybin | 75.42 Mn | 75.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 14.62 Mn |
| Mar 31, 2025 | 14.62 Mn |
| Dec 31, 2024 | -128,137.00 |
| Dec 31, 2024 | -128,137.00 |
| Sep 30, 2024 | -271,229.76 |
| Sep 30, 2024 | -271,229.76 |
| Jun 30, 2024 | -171,818.03 |
| Jun 30, 2024 | -171,818.03 |
| Mar 31, 2024 | 141.64 Mn |
| Mar 31, 2024 | 141.64 Mn |
| Dec 31, 2023 | 29.19 Mn |
| Dec 31, 2023 | 29.19 Mn |
| Sep 30, 2023 | 15.21 Mn |
| Sep 30, 2023 | 15.21 Mn |
| Jun 30, 2023 | 2.62 Mn |
| Jun 30, 2023 | 2.62 Mn |
| Feb 28, 2023 | -26.81 Mn |
| Feb 28, 2023 | -26.81 Mn |
| Dec 31, 2022 | 2.55 Mn |
| Dec 31, 2022 | 2.55 Mn |